Kardigan completes enrollment in two late-stage cardiovascular trials, reports Q3 2026 results
The company finished enrollment in Phase 2b portions of its danicamtiv and ataciguat trials while Phase 3 enrollment continues, with cash of $591.4 million as of September 30, 2026.
Kardigan, Inc. reported financial results for the third quarter ended September 30, 2026, on November 12, 2026, alongside business updates on its three clinical programs.
The company completed enrollment in Cohort 2 of the Phase 2b portion of the KINSHIP-DCM trial of danicamtiv, with topline data expected in the second quarter of 2027, while the Phase 3 trial is now enrolling across both cohorts1. Danicamtiv is a myosin activator being studied in the Phase 2b/3 adaptive, randomized, placebo-controlled KINSHIP-DCM trial in patients with genetic dilated cardiomyopathy.
For ataciguat, an investigational soluble guanylate cyclase activator, Kardigan announced on November 6 the completion of enrollment in the Phase 2b KATALYST-AV trial, with 156 patients, along with baseline data and real-world analyses of roughly 45,000 people with mild-to-moderate aortic stenosis1. The primary endpoint of aortic valve calcium will be assessed at Week 48, alongside measures including aortic valve area, LV mass index, stroke volume index and E/e'1. An update on the Phase 3 trial is expected in the first half of 2027, and topline KATALYST-AV data are expected in the second half of 2027.1
For tonlamarsen, an antisense oligonucleotide targeting hepatic angiotensinogen for acute severe hypertension, enrollment is ongoing in the Phase 2 KARDINAL-ASH trial, with topline data now expected in the second half of 20271.
On the balance sheet, cash, cash equivalents and investments were $591.4 million as of September 30, 2026, compared to $335.5 million as of December 31, 20251, an increase primarily reflecting net proceeds from the company's initial public offering in June 2026, partly offset by cash used in operations1. The company said current cash runway supports continued advancement of danicamtiv, ataciguat and tonlamarsen through clinical data readouts and the initiation of Phase 3 clinical trials across all three programs1.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.